This 2006 case series evaluated three patients with advanced cancers who received high-dose intravenous vitamin C (IVC) therapy. Each patient experienced unexpectedly prolonged survival and clinical improvement. Pharmacokinetic data indicated that IVC achieves plasma concentrations (~14,000 μmol/L) significantly higher than oral administration, levels at which vitamin C exhibits selective cytotoxicity
